Evidence and Insights on Innovative Treatment for Bladder Cancer: Clinical Breakthroughs From Targeted and Immune Options to Antibodies and Gene Therapy
In this activity, experts in bladder cancer present real-world applications of emerging data for innovative therapeutics to offer practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer.
This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of bladder cancer.
Upon completion of this activity, participants should be better able to:
- Discuss the current therapeutic role of novel agents in advanced bladder cancer over multiple lines of treatment and across patient populations
- Summarize updated evidence about the use of novel therapies, including immune checkpoint inhibitors, targeted agents, antibody–drug conjugates, and gene therapy across the spectrum of bladder cancer settings
- Recommend patient-appropriate novel therapeutics for the management of bladder cancer
- Manage unique adverse events associated with novel immune-, targeted-, antibody-, and gene therapy-based treatments for bladder cancer
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Arjun Balar, MD
Associate Professor of Medicine
Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, New York
Arjun Balar, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca/MedImmune; Genentech, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Merck & Co.; Nektar Therapeutics; Pfizer Inc.; and Seattle Genetics, Inc.
Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc.; Immunomedics; Merck & Co., Inc.; Nektar Therapeutics; and Seattle Genetics, Inc. (Research funding to Institution for all except Nektar).
Other Financial or Material Support from Merck & Co., for Steering/Scientific Advisory Committee and Nektar Therapeutics for Steering Committee Membership. AstraZeneca/MedImmune; Genentech, Inc.; and Merck & Co., Inc. for speaking engagements.
Petros Grivas, MD, PhD
Associate Professor, Department of Medicine, Division of Oncology
Clinical Director, Genitourinary Cancers Program
University of Washington
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Petros Grivas, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Pfizer; and Seattle Genetics, Inc.
Grant/Research Support from Bavarian Nordic; Bristol Myers Squibb; Clovis Oncology; Debiopharm Group; Immunomedics; Kure It Cancer Research; Merck & Co., Inc.; Pfizer, Inc; and QED Therapeutics.
Peter H. O’Donnell, MD
Associate Professor of Medicine
Section of Hematology/Oncology, Department of Medicine
The University of Chicago
Peter H. O’Donnell, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Merck & Co., Inc.
Grant/Research Support from Acerta Pharma; AstraZeneca/MedImmune; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Genetech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Seattle Genetics, Inc. Research funding goes to Institution.
Honoraria from Astellas Pharma US, Inc.; Atheneum Partners; The Dedham Group, LLC; Genetech, Inc./F. Hoffmann-La Roche Ltd.; Health Advances LLC; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; MJH Life Sciences; and Seattle Genetics, Inc.
Stock Shareholder in Allergan.
Other Financial or Material Support Travel reimbursement from Genetech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Seattle Genetics, Inc./Astellas Pharma US, Inc.
Other support from Janssen Pharmaceuticals, Inc.; Nektar; and National Institutes of Health.
PVI, PeerView Institute for Medical Education
Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.
Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or [email protected]. Reference course # G6651-21-T.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC Credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.
- 1.00 MOC
- 1.00 AMA PRA Category 1 Credit™
This course is offered through Penn State College of Medicine. To take this course you will be redirected to Penn State College of Medicine's website. You must have an account with Penn State College of Medicine in order to complete this activity.
MOCINGBIRD continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!